GREENBRIER COMPANIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GREENBRIER COMPANIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $3.24B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $3.54B | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $3.94B | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $2.98B | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $1.75B | Oct 25, 2023 |
| FY2022 | Aug 31, 2020 | $2.79B | Oct 31, 2022 |
| FY2019 | Aug 31, 2019 | $914.25M | Oct 29, 2019 |
| FY2019 | May 31, 2019 | $856.15M | Oct 29, 2019 |
| FY2019 | Feb 28, 2019 | $658.67M | Oct 29, 2019 |
| FY2019 | Nov 30, 2018 | $604.52M | Oct 29, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $3.24B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $3.54B | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $3.94B | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $2.98B | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $1.75B | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | $636.43M | Oct 28, 2020 |
| FY2020 | May 31, 2020 | $762.56M | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | $623.85M | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | $769.36M | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | $914.25M | Oct 28, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $607.50M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $558.50M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $441.10M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $306.00M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $231.60M | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | $67.08M | Oct 28, 2020 |
| FY2020 | May 31, 2020 | $107.53M | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | $86.34M | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | $92.19M | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | $133.54M | Oct 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $204.10M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $160.10M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $62.50M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $46.90M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $32.40M | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | ($103.0K) | Oct 28, 2020 |
| FY2020 | May 31, 2020 | $27.77M | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | $13.63M | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | $7.67M | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | $35.11M | Oct 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $360.10M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $324.50M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $176.40M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $118.00M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $41.00M | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | $21.40M | Oct 28, 2020 |
| FY2020 | May 31, 2020 | $66.81M | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | $38.44M | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | $41.78M | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | $76.42M | Oct 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $5.50M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $5.20M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $4.00M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $5.40M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $6.30M | Oct 25, 2023 |
| FY2022 | Aug 31, 2020 | $5.80M | Oct 31, 2022 |
| FY2021 | Aug 31, 2019 | $5.40M | Oct 26, 2021 |
| FY2020 | Aug 31, 2018 | $6.00M | Oct 28, 2020 |
| FY2019 | Aug 31, 2017 | $4.20M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $2.70M | Oct 26, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $263.30M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $247.10M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $235.30M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $225.20M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $191.80M | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | $46.25M | Oct 28, 2020 |
| FY2020 | May 31, 2020 | $49.49M | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | $54.60M | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | $54.36M | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | $60.61M | Oct 28, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $265.70M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $329.60M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $71.20M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | ($150.40M) | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | ($40.50M) | Oct 25, 2023 |
| FY2022 | Aug 31, 2020 | $272.20M | Oct 31, 2022 |
| FY2021 | Aug 31, 2019 | ($21.24M) | Oct 26, 2021 |
| FY2020 | Aug 31, 2018 | $103.34M | Oct 28, 2020 |
| FY2019 | Aug 31, 2017 | $285.60M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $337.17M | Oct 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $4.36B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $4.25B | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $3.98B | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $3.85B | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $3.39B | Oct 25, 2023 |
| FY2022 | Aug 31, 2020 | $3.17B | Oct 31, 2022 |
| FY2021 | Aug 31, 2019 | $2.99B | Oct 26, 2021 |
| FY2020 | Aug 31, 2018 | $2.47B | Oct 28, 2020 |
| FY2019 | Aug 31, 2017 | $2.40B | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $1.84B | Oct 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.53B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $1.38B | Oct 28, 2025 |
| FY2024 | Aug 31, 2023 | $1.25B | Oct 24, 2024 |
| FY2023 | Aug 31, 2022 | $1.28B | Oct 25, 2023 |
| FY2022 | Aug 31, 2021 | $1.31B | Oct 31, 2022 |
| FY2021 | Aug 31, 2020 | $1.29B | Oct 26, 2021 |
| FY2020 | Aug 31, 2019 | $1.28B | Oct 28, 2020 |
| FY2019 | Aug 31, 2018 | $1.25B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $1.02B | Oct 26, 2018 |
| FY2017 | Aug 31, 2016 | $874.31M | Oct 27, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $130.00M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $128.50M | Oct 28, 2025 |
| FY2024 | Aug 31, 2023 | $128.90M | Oct 24, 2024 |
| FY2023 | Aug 31, 2022 | $127.30M | Oct 25, 2023 |
| FY2022 | Aug 31, 2021 | $132.10M | Oct 31, 2022 |
| FY2021 | Aug 31, 2020 | $130.31M | Oct 26, 2021 |
| FY2020 | Aug 31, 2019 | $129.95M | Oct 28, 2020 |
| FY2019 | Aug 31, 2018 | $78.21M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $68.59M | Oct 26, 2018 |
| FY2017 | Aug 31, 2016 | $43.27M | Oct 27, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.20B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $1.04B | Oct 28, 2025 |
| FY2024 | Aug 31, 2023 | $897.50M | Oct 24, 2024 |
| FY2023 | Aug 31, 2022 | $897.70M | Oct 25, 2023 |
| FY2022 | Aug 31, 2021 | $881.70M | Oct 31, 2022 |
| FY2021 | Aug 31, 2020 | $885.46M | Oct 26, 2021 |
| FY2020 | Aug 31, 2019 | $867.60M | Oct 28, 2020 |
| FY2019 | Aug 31, 2018 | $830.90M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $709.10M | Oct 26, 2018 |
| FY2017 | Aug 31, 2016 | $618.18M | Oct 27, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $306.10M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $351.80M | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | $281.70M | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | $543.00M | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | $646.80M | Oct 25, 2023 |
| FY2022 | Aug 31, 2020 | $833.80M | Oct 31, 2022 |
| FY2021 | Aug 31, 2019 | $329.68M | Oct 26, 2021 |
| FY2019 | Aug 31, 2018 | $530.66M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $611.47M | Oct 26, 2018 |
| FY2017 | Aug 31, 2016 | $222.68M | Oct 27, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.75B | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | $1.76B | Oct 28, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 6 | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | 5 | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | 1 | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | 1 | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | 0 | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | 0 | Oct 28, 2020 |
| FY2020 | May 31, 2020 | 0 | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | 0 | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | 0 | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | 1 | Oct 28, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 6 | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | 4 | Oct 28, 2025 |
| FY2025 | Aug 31, 2023 | 1 | Oct 28, 2025 |
| FY2024 | Aug 31, 2022 | 1 | Oct 24, 2024 |
| FY2023 | Aug 31, 2021 | 0 | Oct 25, 2023 |
| FY2020 | Aug 31, 2020 | 0 | Oct 28, 2020 |
| FY2020 | May 31, 2020 | 0 | Oct 28, 2020 |
| FY2020 | Feb 29, 2020 | 0 | Oct 28, 2020 |
| FY2020 | Nov 30, 2019 | 0 | Oct 28, 2020 |
| FY2020 | Aug 31, 2019 | 1 | Oct 28, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 30.87M | Oct 28, 2025 |
| FY2025 | Aug 31, 2024 | 31.14M | Oct 28, 2025 |
| FY2024 | Aug 31, 2023 | 30.88M | Oct 24, 2024 |
| FY2023 | Aug 31, 2022 | 32.60M | Oct 25, 2023 |
| FY2022 | Aug 31, 2021 | 32.40M | Oct 31, 2022 |
| FY2021 | Aug 31, 2020 | 32.70M | Oct 26, 2021 |
| FY2020 | Aug 31, 2019 | 32.49M | Oct 28, 2020 |
| FY2019 | Aug 31, 2018 | 32.19M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | 28.50M | Oct 26, 2018 |
| FY2017 | Aug 31, 2016 | 28.21M | Oct 27, 2017 |